9.4 Immunizations in Special & High-Risk Populations

Immunizations in Special & High-Risk Populations

Executive Summary: Designing immunization care plans for vulnerable populations requires navigating complex immunological windows, contraindications, and blunted vaccine immunogenicity. In immunocompromised individuals and pregnant women, live attenuated vaccines pose severe risks of disseminated viral replication and are absolutely contraindicated. Conversely, patients with anatomical or functional asplenia face catastrophic risks of overwhelming encapsulated bacterial sepsis, requiring a dedicated multi-vaccine protective cocoon (MenACWY, MenB, Pneumococcal, Hib). Clinical pharmacists must also oversee vaccine cold chain integrity and comply with mandatory Vaccine Adverse Event Reporting System (VAERS) reporting.

1. Immunocompromised Hosts: Contraindications & Timing Principles

Defining Severe Immunosuppression

Severe immunocompromise encompasses:

1. High-Dose Systemic Corticosteroids: Prednisone ≥ 20 mg/day (or ≥ 2 mg/kg/day) for ≥ 14 consecutive days. (Low-dose steroids, alternate-day therapy, topical, inhaled, or intra-articular injections do not constitute severe immunosuppression).
2. Biologic & Targeted Immunomodulators: TNF-alpha inhibitors (infliximab, adalimumab, etanercept), anti-CD20 monoclonal antibodies (rituximab), IL-inhibitors, abatacept, JAK inhibitors (tofacitinib, upadacitinib), and antimetabolites (methotrexate >0.4 mg/kg/week, azathioprine >3 mg/kg/day, mycophenolate mofetil).
3. Advanced HIV Infection: CD4 T-lymphocyte count < 200 cells/mm³ (or CD4 percentage < 14%).
4. Hematologic Malignancies & Solid Organ Transplantation: Active chemotherapy, stem cell transplantation (HSCT), or post-transplant calcineurin inhibitor regimens.

Live vs. Inactivated Vaccines in Immunosuppression

• ABSOLUTE CONTRAINDICATION (Live Attenuated Vaccines):
  • Measles, Mumps, Rubella (MMR)
  • Varicella (Varivax) and MMRV (ProQuad)
  • Live Attenuated Influenza Vaccine (LAIV, FluMist)
  • Yellow Fever
  • Oral Typhoid (Ty21a)
  • Rotavirus
• Timing Rules for Live Vaccines:
  • Administer live vaccines at least 4 weeks (≥ 28 days) PRIOR to initiating immunosuppressive therapy.
  • If immunosuppressive therapy has already commenced, defer live vaccines until therapy is discontinued for at least 1 to 3 months (for high-dose corticosteroids or standard chemotherapy) or at least 6 months following B-cell depleting therapies (e.g., rituximab).
• Inactivated & Recombinant Vaccines: Safe to administer because they cannot replicate. However, the patient's quantitative antibody response may be blunted. Recombinant Zoster Vaccine (Shingrix) is specifically recommended for immunocompromised adults aged ≥ 19 years.

2. Anatomical/Functional Asplenia & Complement Deficiencies

The spleen is the primary organ responsible for filtering blood-borne encapsulated bacteria and producing IgM antibodies by splenic marginal zone B-cells. Patients with anatomic asplenia (splenectomy) or functional asplenia (sickle cell disease, hemoglobinopathies, celiac disease with splenic atrophy) and those with persistent complement component deficiencies (C3, C5–C9, properdin, factor D/H) or taking terminal complement inhibitors (eculizumab, ravulizumab) are at astronomical risk for fulminant, fatal encapsulated bacteremia.

The Quadruple Encapsulated Protection Protocol

Splenectomy Timing Rules

• Elective Splenectomy: Administer all indicated vaccines at least 14 days PRIOR to surgery to maximize peak post-operative antibody titers.
• Emergency Splenectomy (e.g., Trauma): Administer vaccines at least 14 days POST-OPERATIVELY (vaccinating immediately post-op results in impaired immune response due to acute surgical immunosuppression).

3. Maternal, Occupational & Chronic Disease Immunization

Pregnancy & Lactation

• Routine Recommended Vaccines During Pregnancy:
  1. Inactivated Influenza Vaccine (IIV4 or RIV4): Administer in any trimester during influenza season. (LAIV is strictly contraindicated).
  2. Tdap: Administer 1 dose during EACH pregnancy at 27–36 weeks of gestation (optimally early in this window).
  3. Updated COVID-19 Vaccine: Administer 1 dose in any trimester.
  4. Maternal RSV Vaccine (Abrysvo ONLY): Administer 1 dose of Pfizer's unadjuvanted bivalent RSV vaccine (Abrysvo) between 32 0/7 and 36 6/7 weeks of gestation during the designated maternal RSV season (typically September through January in contiguous US) to protect neonates against severe RSV lower respiratory disease for up to 6 months after birth. (Note: Arexvy is NOT approved in pregnancy).
• Contraindicated in Pregnancy: All live attenuated vaccines (MMR, Varicella, LAIV). Women receiving live vaccines should avoid pregnancy for at least 4 weeks (28 days).
• Postpartum: Non-immune postpartum women should receive indicated MMR, Varicella, and Tdap immediately prior to hospital discharge. Breastfeeding is NOT a contraindication to any routine maternal vaccine (except yellow fever in rare travel settings).

Chronic Disease Indications: Diabetes & Liver Disease

• Diabetes Mellitus (Type 1 and Type 2):
  • Hepatitis B Series: Recommended for all unvaccinated adults with diabetes aged 19 through 59 years as soon as possible after diagnosis (due to frequent blood glucose monitoring and assisted blood glucose checks); adults aged ≥ 60 years receive Hepatitis B based on clinical assessment and shared decision-making.
  • Pneumococcal (PCV20 or PCV15 + PPSV23), annual Influenza, Shingrix (age ≥ 50), COVID-19, Tdap.
• Chronic Liver Disease (Cirrhosis, Chronic Hep B/C, NAFLD/MASH, Alcohol-Related):
  • Hepatitis A: 2-dose series (Months 0, 6–12) or combined HepA/HepB (Twinrix: 3-dose series at Months 0, 1, 6).
  • Hepatitis B: 2- or 3-dose series (e.g., Heplisav-B 2 doses at 0, 1 month; or Engerix-B/Recombivax HB 3 doses).
  • Pneumococcal, annual Influenza, Shingrix (age ≥ 50), COVID-19.

Healthcare Personnel (HCP)

1. Hepatitis B: Documented 2- or 3-dose series + mandatory post-vaccination serologic testing (anti-HBs titer) drawn 1 to 2 months after the final dose.
   • Anti-HBs ≥ 10 mIU/mL: Considered immune for life (no further boosters or testing needed).
   • Anti-HBs < 10 mIU/mL (Non-Responder): Administer a second complete Hepatitis B vaccine series and repeat anti-HBs testing 1–2 months later. If still < 10 mIU/mL after 2 full series, declare "non-responder" and provide Hepatitis B Immune Globulin (HBIG) following any bloodborne pathogen exposure.
2. MMR & Varicella: 2 documented doses, serologic evidence of immunity, or verified history of varicella.
3. Annual Influenza Vaccine & Tdap: 1 dose Tdap, then Td/Tdap booster every 10 years.

4. Vaccine Storage, Cold Chain Integrity & VAERS Reporting

Cold Chain Management & Temperature Specifications

Maintaining strict temperature control across the entire vaccine lifecycle is mandatory to prevent thermal denaturation of antigens and loss of immunogenicity.

┌────────────────────────────────────────────────────────────────────────┐
│                     VACCINE COLD CHAIN SPECIFICATIONS                  │
├──────────────────────────────────┬─────────────────────────────────────┤
│ REFRIGERATED VACCINES            │ FROZEN VACCINES                     │
│ Temperature: 2°C to 8°C          │ Temperature: -50°C to -15°C         │
│              (36°F to 46°F)      │              (-58°F to 5°F)         │
│ • Inactivated Influenza (IIV4)   │ • Varicella (Varivax)               │
│ • Tdap / Td / DTaP               │ • MMRV (ProQuad)                    │
│ • Hepatitis A / Hepatitis B      │ • MMR (can be refrigerated or       │
│ • HPV (Gardasil 9)               │   frozen; freezer preferred)        │
│ • Pneumococcal (PCV15, PCV20)    │ • Frozen COVID-19 formulations      │
│ • Meningococcal (MenACWY, MenB)  │                                     │
│ • SHINGRIX (Antigen + Adjuvant)  │ • NEVER FREEZE SHINGRIX OR          │
│ • Hib, RSV, Inactivated Polio    │   ALUMINUM-ADJUVANTED VACCINES!     │
└──────────────────────────────────┴─────────────────────────────────────┘

Storage & Handling Best Practices

• Digital Data Loggers (DDL): Use continuous temperature monitoring devices with a buffered probe (immersed in glycol) positioned in the center of the storage unit.
• Placement Rules: Store vaccines in original packaging in the middle of the unit, at least 2–3 inches away from walls, cooling vents, floor, and ceiling. NEVER store vaccines in refrigerator doors, vegetable crisper drawers, or against back walls where temperatures fluctuate wildly.
• Stand-Alone Units: Purpose-built, stand-alone pharmaceutical-grade refrigerators and freezers are strongly preferred over dormitory-style combination units.
• NEVER FREEZE Shingrix: Freezing irreversibly damages the liposomal structure of the AS01B adjuvant. If Shingrix or aluminum-adjuvanted vaccines are accidentally frozen, discard immediately.

Vaccine Adverse Event Reporting System (VAERS)

• Overview: VAERS is a national, passive post-marketing vaccine safety surveillance program co-managed by the CDC and the FDA.
• Mandated Reporting Under NCVIA (1986): Healthcare providers are legally required to report:
  1. Any adverse event listed in the VAERS Table of Reportable Events Following Vaccination occurring within the specified timeframe.
  2. Any adverse event listed by the vaccine manufacturer as a contraindication to subsequent doses in the package insert.
  3. Any serious adverse event (death, life-threatening condition, inpatient hospitalization or prolongation of hospitalization, persistent disability/incapacity, or congenital anomaly), regardless of whether the provider believes the vaccine caused the event.
  4. All vaccine administration errors (e.g., incorrect route, wrong dose, expired product, wrong patient).